Abstract:
Jump Start to GLP1-Agonists
J. Diego Yahuaca, MD PGY 3 Resident, Northwestern McGaw Family Medicine at Humboldt Park

Background:
Dulaglutide is a GLP-1 agonist (GLP1a) that is covered by Medicaid and Medicare part D for Type 2 Diabetes Mellitus (DM2). Many patients at Erie have this insurance coverage and DM2 but are not on GLP1a. Patients who are started on Dulaglutide begin the medication at the lowest dose to minimize side effects, with monthly follow up for dose titration. Often, they are lost to follow up or their follow up is delayed and their dose is not appropriately titrated in a timely manner. The goal of this project is to identify patients with DM2 and coverage by Medicaid and Medicare part D, initiate them on Trulicity, and reinforce appropriate dose titration and regular follow up.

Methods:
Family medicine residency training includes time for patient panel management. We will utilize this time to identify/recruit eligible patients, provide outreach reminders, and conduct supplementary telehealth visits in addition to their regular face-to-face visits for their DM2. The primary outcome is proportion of eligible patients initiated on Dulaglutide. This project is still underway and data collection is expected to be completed.

Results/Conclusions:
In Progress